<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-4NOQCX9Z</identifier><date>2021</date><creator>Anderluh, Marko</creator><creator>Bricelj, Aleša</creator><creator>Sosič, Izidor</creator><relation>documents/doc/4/URN_NBN_SI_doc-4NOQCX9Z_001.pdf</relation><relation>documents/doc/4/URN_NBN_SI_doc-4NOQCX9Z_001.txt</relation><format format_type="issue">2</format><format format_type="volume">72</format><format format_type="type">article</format><format format_type="extent">str. 100-106</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">64793091</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-4NOQCX9Z</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Farmacevtska kemija</subject><subject language_type_id="slv">himerni razgrajevalci</subject><subject language_type_id="slv">ligaze E3</subject><subject language_type_id="slv">proteasom</subject><subject language_type_id="slv">razgradnja proteinov</subject><title>Tarčna razgradnja proteinov z uporabo himernih molekul</title><title>Utilizing proteolysis-targeting chimeras for targeted protein degradation</title></Record>